Pediatric inflammatory bowel disease (IBD) is no longer rare, and it’s no longer acceptable to treat it with outdated tools and timelines. Pediatric IBD accounts for approximately 25% of all newly diagnosed IBD patients. Clinical experience confirms that although the…
Despite significant advancements in biologic therapy for pediatric inflammatory bowel disease (IBD), loss of response (LOR) remains a major challenge in clinical management. Infliximab (IFX) and Vedolizumab (VEDO), both widely used monoclonal antibodies, offer disease-modifying benefits, yet many pediatric patients…
Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody formation, variable drug clearance, and the high costs associated with frequent dosing. In many cases, biologics are introduced only in…
TuMinimize™ enables oncologists to deliver optimal drug dosing for each patient Fort Myers, FL – June 18, 2024 — Baysient®, a leading provider of therapeutic drug monitoring (TDM) software, today announced the launch of TuMinimize™, a web-based nomogram/algorithm designed to…
In a significant stride for improving oncology treatment, Baysient® has announced its latest innovation: a groundbreaking therapeutic drug monitoring (TDM) software tailored for oncology drugs, coming soon in 2024. This TDM solution takes a Compuceutical approach, merging advanced cloud-based software…
Built to provide individualized treatments for patients with improved outcomes, Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products. Physicians can harness the power of iDose® and T3®, our innovative web-based applications,…
Baysient announces updates to its therapeutic drug monitoring app Time To Target (T3) to enable clinicians to deliver personalized dosing recommendations for the subcutaneous forms of Infliximab and adalimumab. Inflammatory bowel disease (IBD) is a chronic condition affecting approximately 3…
Marla Dubinsky, MD, Discusses Patient Success with Dashboard-Guided Infliximab Induction in Gastroenterology & Endoscopy News Article Baysient’s patented iDose system uses Bayesian models, laboratory data, and demographics to individualize Infliximab dosing, effectively improving inflammatory bowel disease (IBD) patient outcomes. Marla…
Coronavirus (COVID-19) is officially a worldwide pandemic as it continues to spread globally. The doctors and researchers on the Baysient team are actively developing treatments for COVID-19 to help end the death toll it has caused around the world. For…
